PMC:3951193 / 7544-8870 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/3951193","sourcedb":"PMC","sourceid":"3951193","source_url":"http://www.ncbi.nlm.nih.gov/pmc/3951193","text":"Data Sources and Search Parameters\nThis review followed the guidelines proposed by PRISMA, the Preferred Reporting Items for Systematic Reviews and Meta-Analyses [24], see Checklist S1. PubMed (www.ncbi.nlm.nih.gov/pubmed/) was searched through March 2013 using three MeSH keywords: endocannabinoids, cannabinoids, cannabinoid receptors. Each keyword was entered in a boolean combination with each of the intervention groups listed in the previous paragraph. Titles and abstracts of identified articles in all languages were screened for inclusion and exclusion criteria. We included randomized clinical trials, observational studies, and preclinical research on model organisms and in vitro studies. We excluded redundant articles that used identical methods and reported parallel results, or review articles that presented duplicate information.\nBecause this review focuses upon clinical interventions affecting the eCB system, we deemed as irrelevant (and excluded) articles that described the reverse scenario, such as eCB ligands modulating opioid receptors, THC enhancing tobacco or alcohol abuse, etc. Retrieved articles were scanned for supporting citations, and antecedent sources were retrieved and screened for inclusion and exclusion criteria. In addition, we checked reference lists of relevant narrative reviews.","divisions":[{"label":"Title","span":{"begin":0,"end":34}}],"tracks":[{"project":"2_test","denotations":[{"id":"24622769-19621070-95790172","span":{"begin":163,"end":165},"obj":"19621070"}],"attributes":[{"subj":"24622769-19621070-95790172","pred":"source","obj":"2_test"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"2_test","color":"#ae93ec","default":true}]}]}}